8-K: OptiNose Reports Q2 2024 Results, Narrows Revenue Guidance, and Highlights Formulary Wins

OptiNose announced its second quarter 2024 financial results, highlighted by a 5% increase in XHANCE net revenue compared to Q2 2023, and narrowed its full-year revenue guidance while increasing its average net revenue per prescription guidance.

Summary

• OptiNose reported a 5% increase in XHANCE net revenue for the second quarter of 2024, reaching $20.5 million, compared to $19.5 million in the same period last year.
• For the first six months of 2024, XHANCE net revenue totaled $35.4 million, a 13% increase compared to the same period in 2023.
• The company's net loss for Q2 2024 was $7.6 million, or $0.07 per share, and $21.6 million, or $0.17 per share, for the first six months of the year.
• OptiNose has narrowed its full-year 2024 XHANCE net revenue guidance to between $85.0 and $90.0 million, down from the previous range of $85.0 to $95.0 million.
• The company increased its expected average net revenue per prescription for 2024 to at least $250, up from the previous guidance of at least $230.
• Operating expenses for 2024 are projected to be between $95.0 and $101.0 million, including approximately $6.0 million in stock-based compensation.
• XHANCE was added to Express Scripts national formularies, covering over 24 million lives, which is expected to improve insurance access.
• A registered direct offering in May 2024 raised approximately $55 million, which is expected to fund operations and debt service through 2025.
• The company's cash and cash equivalents stood at $91.4 million as of June 30, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue growth, formulary wins, and increased average net revenue per prescription. However, the net loss and narrowed revenue guidance temper the overall optimism.

Positives

• XHANCE net revenue showed growth in both Q2 and year-to-date periods.
• The average net revenue per prescription has significantly increased, indicating improved profitability.
• The addition of XHANCE to Express Scripts national formularies expands market access.
• The $55 million capital raise strengthens the company's financial position.
• The company expects to achieve peak net revenue of at least $300 million and positive income from operations for full year 2025.
• The company has narrowed its full year revenue guidance to a more achievable range.
• The company has increased its average net revenue per prescription guidance.

Negatives

• The company experienced a net loss of $7.6 million in Q2 2024 and $21.6 million for the first six months of the year.
• Operating expenses increased by approximately $4 million in Q2 2024 compared to Q2 2023.
• The full-year 2024 XHANCE net revenue guidance was narrowed to $85-$90 million, which is a reduction of the top end of the previous guidance of $95 million.

Risks

• Physician and patient acceptance of XHANCE for its new indication is a risk.
• Maintaining adequate third-party reimbursement for XHANCE is crucial.
• The prevalence of chronic sinusitis and market opportunities for XHANCE may be smaller than expected.
• The company's ability to efficiently generate XHANCE prescriptions and net revenues is a risk.
• Unanticipated costs and expenses could impact financial performance.
• There is potential for varying interpretation of the results from the ReOpen program.
• The company's ability to comply with debt covenants is a risk.
• Intellectual property and competitive products pose risks.
• Changes to the XHANCE co-pay assistance program could impact revenue.

Future Outlook

The company expects its current cash and cash equivalents to be sufficient to fund its operations and debt service obligations through 2025. They also anticipate achieving peak net revenue of at least $300 million and positive income from operations for full year 2025.

Management Comments

• This is the first quarter in which we are executing on the launch of our new first-and-only label indication for chronic sinusitis, also called chronic rhinosinusitis without nasal polyps, which gives us access to a greatly expanded total addressable market, stated CEO Ramy Mahmoud, MD, MPH.
• We believe the addition of XHANCE to Express Scripts preferred formularies late in the second quarter is an example of gradually improving insurance barriers with our new first-and-only approval.
• Improving insurance barriers, in conjunction with consistent efforts to disseminate highly differentiated clinical results to both old and new prescribers, are important enablers of our future revenue growth trajectory.

Industry Context

The announcement highlights OptiNose's efforts to expand the market for XHANCE by targeting chronic sinusitis without nasal polyps, a significant patient population. The addition to Express Scripts formularies is a positive step in improving market access and reimbursement, which are critical for the success of pharmaceutical products. The company is also focusing on prescriber education and outreach to drive adoption of XHANCE.

Comparison to Industry Standards

• OptiNose's revenue growth of 5% in Q2 2024 is modest compared to some high-growth biotech companies, but it is a positive sign given the challenges of launching a new indication.
• The increase in average net revenue per prescription is a key indicator of improved pricing and profitability, which is a focus for many pharmaceutical companies.
• The addition of XHANCE to Express Scripts national formularies is a significant achievement, as it provides access to a large patient population, similar to what other companies seek with their products.
• The company's focus on prescriber education and outreach is a common strategy in the pharmaceutical industry to drive adoption of new products.
• The company's expectation to achieve peak net revenue of at least $300 million and positive income from operations for full year 2025 is an ambitious goal, but it is in line with the growth expectations of other specialty pharmaceutical companies.

Stakeholder Impact

• Shareholders will be impacted by the financial results and future outlook.
• Employees will be impacted by the company's performance and growth.
• Customers (patients) will benefit from improved access to XHANCE.
• Suppliers and creditors will be impacted by the company's financial health.

Next Steps

• The company will continue to focus on the launch of XHANCE for its new indication.
• They will continue to improve insurance access and coverage for XHANCE.
• The company will continue to educate and outreach to prescribers.
• The company will continue to focus on growing profitable prescriptions.

Key Dates

Keywords

XHANCE, chronic sinusitis, net revenue, prescription, formulary, Express Scripts, financial results, operating expenses, pharmaceutical, ENT, allergy